2 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
Follow elbion AG: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB) ELB245, Tolterodine - Overactive Bladder, Urinary Incontinence | Phase 2 | Terminated | elbion AG | 275 | 2007-02-01 | 2007-08-08 |
| ELB139 Given Orally to Patients With Concurrent Panic Disorder, Challenged by CO2 Inhalation After a Single Dose and One Week of Treatment ELB139 - Panic Disorder | Phase 2 | Terminated | elbion AG | 24 | 2006-05-01 | 2006-09-29 |
Panic Disorder (1) · Urinary Bladder, Overactive (1) · Urinary Incontinence (1)
1-(4-chlorophenyl)-4-piperidin-1-yl-1,5-dihydroimidazol-2-one (1) · Tolterodine Tartrate (1)
Germany (2) · Netherlands (1) · Poland (1) · Sweden (1)
Eric Griez, Prof Dr (1) · Martin Michel, Prof. (1)